Photo: Abovfold | CC BY-SA 4.0 | Wikimedia Commons
FDA Panel Vote On Unapproved Peptides Sparks Concerns Over Prescribing Surge
An FDA advisory panel voted on Friday, July 24, 2026, in Washington, D.C., to broaden access to four unapproved peptides, a move experts warn could spark a rapid surge in prescribing.[1]
The panel met in Washington, D.C., for a two-day FDA advisory session that began Thursday, July 23, 2026, and its recommendation to broaden compounding access is nonbinding.[2] The 20-member outside panel includes at least seven doctors or pharmacists with financial ties to the peptide industry.[2] FDA career scientists and outside experts warned there is insufficient safety and efficacy evidence for peptides such as BPC-157 and TB-500.[2]
During the Biden administration, the FDA added nearly 20 peptides to a "do not compound" list, saying the products posed "significant safety risks" because of limited testing.[3] Many peptides are sold online as "research use only" products in a gray market that can include contamination or impurities.[3] Some clinicians argue that regulated compounding would at least bring patients into clinics rather than leaving them to a risky online trade.[3]
Early coverage from CBS emphasized clinicians' skepticism and repeated warnings that the peptides lack robust human evidence.[4] Later reporting in the New York Times stressed that the panel's vote could prompt telehealth and wellness clinics to market the peptides more aggressively, potentially fueling off-label prescribing.[1]
Show source details & analysis (7 sources)
📌 Key Facts
- The FDA advisory panel began a two‑day meeting in Washington, D.C., on Thursday, July 23, 2026, to review safety and evidence for allowing compounding pharmacies to produce seven popular peptides (FDA advisory panel).
- HHS Secretary Robert F. Kennedy Jr. has publicly called himself a “big fan” of peptides, said he has used them personally, and has vowed to overturn prior restrictions — a stance that has heightened concerns about political pressure around the review (HHS Secretary Robert F. Kennedy Jr.).
- The 20‑member outside advisory panel includes at least seven doctors or pharmacists with financial ties to the peptide industry (owners of wellness clinics, compounding pharmacies and online consultancies), and the FDA added additional non‑industry academics earlier in the week to address conflicts of interest concerns (20‑member outside advisory panel).
- FDA career scientists and outside experts warned there is insufficient safety and efficacy evidence for many of the peptides under review — including BPC‑157 and TB‑500 — and urged caution before broadening access (BPC-157).
- Many of the peptides are currently sold online as “research use only” products in a gray market that can involve contamination or impurities, and some clinicians say allowing regulated compounding could steer patients away from unsafe online vendors (online "research use only" products).
- On Friday, July 24, 2026, the advisory panel voted to broaden access to four of the unapproved peptides under review; the committee’s recommendations are nonbinding (voted to broaden access).
- The New York Times reported that some panelists and outside experts warned the panel’s recommendation could trigger a rapid increase in off‑label prescribing, and that telehealth and wellness clinics are preparing to market these peptides more aggressively for weight loss, anti‑aging and performance enhancement (telehealth and wellness clinics).
- During the Biden administration the FDA added nearly 20 peptides to its “do not compound” list, citing “significant safety risks” from limited testing, and many advisers and staff involved in those decisions have since left the agency (do not compound list).
- Rita Jew, president of the Institute for Safe Medication Practices, called proposals to widen peptide access despite minimal clinical data “really alarming,” noting few other injected substances have such limited testing (Rita Jew).
📰 Source Timeline (7)
Follow how coverage of this story developed over time
July 24, 2026
9:15 PM
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
New information:
- The New York Times article, published July 24, 2026, details that some advisory panel members and outside experts are warning the vote could trigger a rapid increase in off-label prescribing of the four unapproved peptides once compounding restrictions are eased.
- The story reports additional specifics on how telehealth and wellness clinics are preparing to market these peptides more aggressively if FDA follows the panel’s recommendation, raising worries about lightly supervised use for weight loss, anti-aging and performance enhancement.
- The article adds more detail on internal FDA and outside-ethics concerns about panel members’ financial ties to peptide manufacturers and clinics, beyond the general conflict-of-interest issues previously noted, and describes debate inside the meeting over whether political pressure from HHS leadership is influencing the process.
- It underscores that the panel’s recommendation would allow compounding pharmacies to produce these peptides without the usual new-drug approval data, and that some panelists explicitly predicted a sharp rise in use even in the absence of robust clinical trials.
4:53 PM
FDA panel considers loosening regulations on certain unapproved peptides
New information:
- On Thursday, July 23, 2026, the FDA advisory panel voted to broaden access to four of the unapproved peptides under review.
- As of Friday, July 24, 2026, the panel is in the second day of its meetings on whether to loosen restrictions on certain unapproved peptide drugs.
July 23, 2026
3:26 PM
FDA panel to consider loosening regulations for some peptides
New information:
- The CBS article, published Thursday, July 23, 2026, reiterates that the FDA advisory panel will spend two days weighing whether compounding pharmacies may fill prescriptions for seven unapproved peptide therapies.
- It details that HHS Secretary Robert F. Kennedy Jr. has publicly called himself a "big fan" of the unapproved peptides and said he has personally used them for injuries, underscoring political pressure around the meeting.
- The article names BPC-157 as one of the peptides under discussion and notes that NYU Langone endocrinologist Dr. Rachel Pessah-Pollack says BPC-157 has been tested in only about 30 humans, contrasting that with hundreds of thousands of patients studied for GLP-1 drugs.
- It quotes IVIM Health chief medical officer Dr. Jessica Duncan, who plans to testify before the panel, arguing that because patients will seek out these therapies, the FDA should ensure they can be provided by doctors in a clinical setting rather than in an online gray market.
- The piece highlights that many peptides are currently sold online as "research use only" products in a gray market that experts warn can involve contamination or impurities, with Pessah-Pollack cautioning that such products could contain toxic substances like arsenic or lead.
- The article notes that during the Biden administration the FDA added nearly 20 peptides to the agency's 'do not compound' list, with prior FDA language describing those substances as presenting "significant safety risks" due to limited testing, and that many of the advisers and staff involved in those decisions have since left the agency.
- Former FDA official Dr. Peter Lurie is quoted saying that, given Kennedy's public support for peptides, he doubts the upcoming advisory panel hearing will be an "honest investigation" and believes "everybody knows the outcome that the secretary wants."
2:12 PM
WATCH LIVE: FDA advisory panel considers use of peptides
New information:
- The FDA advisory meeting formally began on Thursday, July 23, 2026, in Washington, D.C., marking Day 1 of the scheduled two-day session.
- HHS Secretary Robert F. Kennedy Jr. has publicly described himself as a "big fan" of peptides and has vowed to overturn restrictions imposed under President Joe Biden, and this FDA meeting has his backing.
- The 20-member outside advisory panel includes at least seven doctors or pharmacists with financial ties to the peptide industry, such as owners of wellness clinics, peptide-compounding pharmacies, and online consulting businesses.
- Earlier in the week, FDA added additional experts without industry ties to the panel, including academics, to balance conflicts of interest concerns.
- Rita Jew, president of the Institute for Safe Medication Practices, warned that allowing wider peptide access despite minimal evidence is "really alarming" because there are few other substances people inject with such limited clinical data.
- FDA career scientists remain unconvinced there is sufficient safety and efficacy evidence to support compounding of the peptides, including BPC-157 and TB-500, which FDA has previously warned the public about.
- The committee will vote on whether seven popular peptides should be added to the agency's list of substances eligible for pharmacy compounding, though its votes will be nonbinding.
1:17 PM
Health experts issue caution over unapproved peptides as FDA weighs easing restrictions
New information:
- CBS reports on July 23, 2026, that health experts are publicly urging caution about allowing compounded access to the seven peptides, citing a lack of robust research.
- The CBS segment frames the FDA’s July 23-24 advisory committee as focused on whether compounding pharmacies can dispense these seven unapproved peptides with a doctor’s prescription for special medical conditions, underscoring concern over off-label or lightly evidenced uses.
- The piece highlights that, despite growing demand for peptide therapies, some clinicians remain skeptical of easing restrictions before more clinical data are available.
11:39 AM
U.S. signs nuclear deal with Saudi Arabia. And, Nolan Wells' independent autopsy results
New information:
- The NPR Up First newsletter reiterates that the FDA advisory committee begins its two‑day meeting on Thursday, July 23, 2026, to consider whether compounding pharmacies should be allowed to produce seven popular peptides, and frames the meeting’s start as occurring “starting today.”
- It confirms the meeting’s structure as a two‑day session in which the panel will review safety and evidence for compounding these largely unapproved peptide therapies.